444912-51-0 Usage
Uses
1. Used in Pharmaceutical Industry:
Methanone, (2-iodo-5-nitrophenyl)[1-[[(2R)-1-methyl-2-piperidinyl]methyl]-1H-indol-3-yl]is used as a synthetic cannabinoid for its ability to selectively bind to cannabinoid (CB) receptors. It has greater than 100-fold selectivity for the CB2 receptor over the CB1 receptor, making it a potential candidate for the development of targeted therapies.
2. Used in Pain Management:
Methanone, (2-iodo-5-nitrophenyl)[1-[[(2R)-1-methyl-2-piperidinyl]methyl]-1H-indol-3-yl]acts as an agonist at human CB2 receptors, which are involved in pain modulation. It has been shown to produce antinociception to thermal pain in rats, indicating its potential use in pain management applications.
3. Used in Research and Development:
Due to its unique chemical structure and receptor selectivity, Methanone, (2-iodo-5-nitrophenyl)[1-[[(2R)-1-methyl-2-piperidinyl]methyl]-1H-indol-3-yl]can be used in research and development for studying the effects of synthetic cannabinoids on CB2 receptors and their potential therapeutic applications.
4. Used in Drug Delivery Systems:
Similar to gallotannin, Methanone, (2-iodo-5-nitrophenyl)[1-[[(2R)-1-methyl-2-piperidinyl]methyl]-1H-indol-3-yl]may also benefit from novel drug delivery systems to enhance its bioavailability and therapeutic outcomes. These systems could include organic and metallic nanoparticles as carriers for improved delivery and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 444912-51-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,4,9,1 and 2 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 444912-51:
(8*4)+(7*4)+(6*4)+(5*9)+(4*1)+(3*2)+(2*5)+(1*1)=150
150 % 10 = 0
So 444912-51-0 is a valid CAS Registry Number.
444912-51-0Relevant articles and documents
In vitro pharmacological characterization of AM1241: A protean agonist at the cannabinoid CB2 receptor?
Yao,Mukherjee,Fan,Garrison,Daza,Grayson,Hooker,Dart,Sullivan,Meyer
, p. 145 - 154 (2006)
Background and purpose: The CB2 receptor has been proposed as a novel target for the treatment of pain, and CB2 receptor agonists defined in in vitro assays have demonstrated analgesic activity in animal models. Based on its in vivo analgesic efficacy, AM1241 has been classified as a CB2-selective agonist. However, in vitro characterization of AM1241 in functional assays has not been reported. Experimental approach: In this study, AM1241 was characterized across multiple in vitro assays employing heterologous recombinant receptor expression systems to assess its binding potencies at the human CB2 and CB1 receptors and its functional efficacies at the human CB2 receptor. Key results: AM1241 exhibited distinct functional properties depending on the assay conditions employed, a unique profile in contrast to those of the agonist CP 55,940 and the inverse agonist SR144528. AM1241 displayed neutral antagonist activities in FLIPR and cyclase assays. However, when cyclase assays were performed using lower forskolin concentrations for stimulation, AM1241 exhibited partial agonist efficacy. In addition, it behaved as a partial agonist in ERK (or MAP) kinase assays. Conclusions and implications: The unusual phenomenon of inconsistent functional efficacies suggests that AM1241 is a protean agonist at the CB 2 receptor. We postulate that functional efficacies displayed by protean agonists in various assay systems may depend on the levels of receptor constitutive activities exhibited in the assay systems, and therefore, efficacies observed in in vitro assays may not predict in vivo activities.
